



Preferred Drug List

NEW DRUG REVIEW

Proprietary Name: Revlimid®

Common Name: Lenalidomide

PDL Category: Antineoplastics – Miscellaneous

<u>Comparable Products</u>	<u>Preferred Drug List/ Recommended Drug List Status</u>
Aranesp	Non-Preferred
Procrit	Preferred

Summary

Indications and Usage: Treatment of anemia in patients with deletion 5q type myelodysplastic syndrome or multiple myeloma when combined with dexamethasone

Dosage Forms: Capsules; 5mg, 10mg, 15mg, and 25mg

Recommended Dosage: 5-10mg by mouth once daily; initial dose should be 10mg daily and adjusted based on platelets and ANC.

Common Adverse Drug Reactions: Diarrhea, pruritus, rash, fatigue, nausea, nasopharyngitis, arthralgia, pyrexia, back pain, peripheral edema, cough, dizziness, headache.

Contraindications: Pregnancy, thrombosis risk, impaired renal function, hypersensitivity to any component of the product

Manufacturer: Celgene Corporation

Analysis: Revlimid® is only available through a restrictive distribution program called Revassist due to potential toxicity and to avoid fetal exposure. Only prescribers and pharmacists registered with this program may prescribe and dispense Revlimid®. Other medications used for the treatment of anemia appear on the PDL as preferred products and are more cost effective. The limitation to access to the product, it not being recommended for use as a first line treatment for the diagnosis of multiple myeloma, and that it has to be combined with another medication (dexamethasone) to achieve its effectiveness, contributes to its recommendation to be added to the RDL as a non-recommended drug.

IME Recommendation:

<input type="checkbox"/> Preferred Drug	<input type="checkbox"/> Recommended Drug
<input type="checkbox"/> Non-Preferred Drug	<input checked="" type="checkbox"/> Non-Recommended Drug
<input type="checkbox"/> Preferred Drug with Conditions	